Afexa Life Sciences Inc.
TSX : FXA

Afexa Life Sciences Inc.

June 01, 2009 17:20 ET

Afexa Life Sciences Announces Change in Senior Management

EDMONTON, ALBERTA--(Marketwire - June 1, 2009) - Afexa Life Sciences Inc. (the "Company") (TSX:FXA) announced today that Ross Montagano, Chief Operating Officer, will be leaving the Company effective June 1, 2009, as part of an internal corporate restructuring. Mr. Montagano will continue to be available to the Company during a transition period.

The Company wishes Mr. Montagano success in his future endeavors and thanks him for his dedication and efforts on our behalf over the past two years.

Mr. Jack Moffatt, Executive Chair will continue to lead the Company's day-to-day operations.

ABOUT AFEXA LIFE SCIENCES INC.

Afexa Life Sciences Inc., founded in 1992, strives to transform people's lives to be healthier and happier by focusing on prevention and recovery through the use of evidence-based naturally-derived health products. The Company's lead product COLD-FX® strengthens the immune system and is widely used as a leading over the counter remedy ("OTC") for helping to prevent and relieve cold and flu infections. On April 1, 2009, the Company changed its name from CV Technologies Inc. to Afexa Life Sciences Inc.

Advisory Regarding Forward-Looking Statements

This news release and contains certain forward-looking statements and information within the meaning of applicable securities laws, which reflect current expectations of the management of Afexa Life Sciences Inc. (the "Company") regarding future events or the Company's future performance, including, without limitation, statements relating to the timing and/or initiation of clinical trials, clinical trial results, the introduction of new products, associated regulatory clearances, economic or financial trends or expectations, financing, acceptance of the Company's products in the marketplace and the hiring or retention of personnel. Forward-looking statements are often, but not always, identified by the use of words such as "expect", "anticipate", "seek", "aim", "continue", "estimate", "objective", "ongoing", "may", "will", "would", "project", "predict", "potential", "could", "should", "might", "believe", "plan", "target", "intend" and similar expressions. All statements other than statements of historical fact contained in this news release may be forward-looking statements. The forward-looking information included in this document does not guarantee future performance and should not be unduly relied upon. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking information, including, without limitation, the impact of competition, the incidence of cold and flu, consumer confidence and spending levels, general economic conditions, interest and currency exchange rates, unseasonable weather patterns, the cost and availability of capital and grants/funding, product development uncertainties and labour market challenges. The Company believes that the expectations and assumptions reflected in the forward-looking information contained herein are reasonable but no assurance can be given that these expectations and assumptions are correct or that that the results, performance or achievements expressed in, or implied by, forward-looking statements herein will occur, or if they do, that any benefits may be derived from them. The Company can give no assurance that new product development initiatives will lead to new product commercialization. The Company assumes no duty to update or revise forward looking information, except as may be required pursuant to applicable laws. All forward-looking information is expressly qualified in its entirety by this cautionary statement. Further information regarding risks and uncertainties relating to the Company and its securities can be found in the disclosure documents filed by the Company with the securities regulatory authorities, available at www.sedar.com. The Company claims exemption under U.S. SEC Rule 12g3-2(b).

Contact Information

  • Afexa Life Sciences Inc. - Financial Contact:
    Allan Cleiren
    Chief Financial Officer
    (780) 432-0022
    Email: acleiren@afexa.com
    or
    Afexa Life Sciences Inc. - Investor Contact:
    Jane Tulloch
    Senior Director, Investor Relations
    (780) 577-3724
    Email: jtulloch@afexa.com
    Website: www.afexa.com